Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05198934 · ClinicalTrials.gov registry record · Phase 3

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

A Phase 3 study of Colorectal Cancer (CRC), sponsored by Amgen.

Active
Registry status
Phase 3
Development phase
160
Enrollment target
20
Study locations

NCT05198934 is a Phase 3 study of Colorectal Cancer (CRC) that is active but no longer recruiting, run by Amgen. The registered enrollment target is 160 participants, below the 394-participant average among 19 other Colorectal Cancer (CRC) trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05198934, a Phase 3 study of Colorectal Cancer (CRC), is active but no longer recruiting, sponsored by Amgen.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
160 participants
Enrollment target
20
Study locations

Study Summary

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).

Conditions Studied

Colorectal Cancer (CRC)

Interventions

  • DRUG Regorafenib
  • DRUG Sotorasib
  • DRUG Panitumumab
  • DRUG Trifluridine and Tipiracil

Study Locations (20)

Michigan

  • University of Michigan - Ann Arbor
  • Revive Research Institute - Farmington Hills
  • Sparrow Clinical Research Institute - Lansing
  • Revive Research Institute - Sterling Heights

Texas

  • Kelsey Research Foundation - Houston
  • Best Cancer Care & Hematology - Houston
  • Lumi Research - Kingwood

California

  • City of Hope National Medical Center - Duarte
  • University of California Irvine - Orange

Florida

  • Cancer Specialists of North Florida - Jacksonville
  • Lakes Research LLC - Miami Lakes

New York

  • Upstate University Hospital - Syracuse
  • White Plains Hospital Center for Cancer Care - White Plains

Alabama

  • Central Alabama Research - Birmingham

District of Columbia

  • Johns Hopkins University School of Medicine - Washington D.C.

Georgia

  • Northwest Georgia Oncology Centers PC - Marietta

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2022-04-19
Est. Completion 2026-05-14
Phase Phase 3

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05198934

The ClinicalTrials.gov registry entry for NCT05198934 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 394-participant average among 19 other Colorectal Cancer (CRC) trials with a reported enrollment target (59% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colorectal Cancer (CRC) appearing as the primary indexed condition, and to 4 interventions - of which Regorafenib is the first listed.

NCT05198934 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Michigan, Texas, California.

Frequently Asked Questions

What is clinical trial NCT05198934 about?

NCT05198934 is a clinical study titled "Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation". The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib...

What is the current status of trial NCT05198934?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2022-04-19. Estimated completion is 2026-05-14.

What conditions does trial NCT05198934 study?

This clinical trial studies the following conditions: Colorectal Cancer (CRC).

What interventions are being tested in trial NCT05198934?

The interventions under investigation include: Regorafenib (DRUG), Sotorasib (DRUG), Panitumumab (DRUG), Trifluridine and Tipiracil (DRUG).

Who is sponsoring clinical trial NCT05198934?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05198934 being conducted?

This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer (CRC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer (CRC)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.